Critical appraisal:Passlick B, Kubuschock B, Sienel W, Thetter O, Pantel K, Izbicki JR 2002 3
From Cancer Guidelines Wiki
Critical Appraisal
Article being appraised
Passlick B, Kubuschock B, Sienel W, Thetter O, Pantel K, Izbicki JR. Mediastinal lymphadenectomy in non-small cell lung cancer: effectiveness in patients with or without nodal micrometastases - results of a preliminary study. Eur J Cardiothorac Surg 2002 Mar;21(3):520-6 [Abstract available at http://www.ncbi.nlm.nih.gov/pubmed/11888774].
Applicable clinical question
What is the clinical benefit of mediastinal lymph node dissection in stage IIIA operable NSCLC?
Key Facts
Study Design
randomised controlled trial
Number of Patients
201
Includes an economic evaluation
no
Evidence ratings
Level of evidence
II
Quality of evidence
| High | Additional comments: Well designed RCT. |
Size of effect
| 2 | Reason for decision: The point estimate of effect is clinically important BUT the confidence interval includes clinically unimportant effects. |
Relevance of evidence
| 1 | Additional comments: Evidence of an effect on patient‐relevant clinical outcomes including benefits and harms, and survival. |
Result of appraisal
Included
Reason for decision
Completed by
This appraisal has been completed.- Article
- Passlick B, Kubuschock B, Sienel W, Thetter O, Pantel K, Izbicki JR. Mediastinal lymphadenectomy in non-small cell lung cancer: effectiveness in patients with or without nodal micrometastases - results of a preliminary study. Eur J Cardiothorac Surg 2002 Mar;21(3):520-6 [Abstract available at http://www.ncbi.nlm.nih.gov/pubmed/11888774].
- Assigned to
- User:Gavin.wright
- Topic area
- Guidelines:Lung cancer/Treatment/Non-small-cell stage III operable
- Clinical question
- Clinical question:Lung cancer/Treatment/Non-small-cell stage III operable/What is the clinical benefit of mediastinal lymph node dissection in stage III operable NSCLC?
Section below only relevant for Cancer Council Project Officer
